Matches in Nanopublications for { ?s ?p "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP256208.RAr1W5nPJxhLK8KE8Enfm-k17KtR1Pq6ueV2ZUteVOYNY130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP256208.RAr1W5nPJxhLK8KE8Enfm-k17KtR1Pq6ueV2ZUteVOYNY130_provenance.
- NP730573.RAA4GbvWFGZ9SSnU3GG8yw08mQ1ylzxhvKoKlivfg4-Bw130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP730573.RAA4GbvWFGZ9SSnU3GG8yw08mQ1ylzxhvKoKlivfg4-Bw130_provenance.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.
- NP542126.RAy2ZrQ1-rwvzkghroZXEqmMO5eWWT8rDORRhNwe6Y2bI130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP542126.RAy2ZrQ1-rwvzkghroZXEqmMO5eWWT8rDORRhNwe6Y2bI130_provenance.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.
- NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604772.RAfcMgvLIssJfBEy0QFiSSKXAvIKk_bMd9PE5asQKF6FQ130_provenance.